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Abstract
Introduction Pancreatic cancer (PC) is the sixth leading
cause of cancer death in Australia and the fourth in the
United States, yet research in PC is lagging behind that in
other cancers associated with a high disease burden. In the
absence of agreed processes to reliably identify research
areas which can deliver signiﬁcant advances in PC
research, the Cancer Council NSW established a strategic
partnership with the NSW Pancreatic Cancer Network to
deﬁne critical research issues and opportunities that could
accelerate progress in this ﬁeld in Australia.
Materials and methods The process consisted of ﬁve
distinct stages: a literature review on recent progress in PC
research, semi-structured expert interviews, a Delphi pro-
cess, consumer focus groups, and a nominal group process.
Information collected at each step informed the develop-
ment of subsequent stages.
Results The results from these steps were reﬁned by the
nominal group into a set of seven speciﬁc pancreatic cancer
research goals. The goals were disseminated and led to a
new funding scheme for key PC research priorities.
Discussion This prioritisation exercise provided a much
needed ‘‘road map’’ for research prioritisation in PC and
served as a checklist to researchers applying for PC
research grants to conﬁrm how their research can contrib-
ute towards accelerating progress in PC research in
Australia.
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Introduction
Pancreatic cancer (PC) is the sixth leading cause of cancer
death in Australia [1] and the fourth in the United States,
[2] as disease outcomes remain dismal, with single digit
5-year survival rates both in Australia [3] and elsewhere
[2]. Despite this, research in PC is lagging behind than in
other cancers, [4] with only 1% of the research budget of
the US National Cancer Institute being spent on PC [5].
In the absence of agreed processes to reliably identify
research areas that can deliver signiﬁcant advances in PC
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strategic partnership with the NSW Pancreatic Cancer
Network to systematically deﬁne critical research issues
and opportunities that could accelerate progress in this ﬁeld
in Australia.
Here, we describe the priority-setting process, the out-
puts generated at each stage and how they informed PC
research funding decisions.
Materials and methods
The study commenced with a wide consultation with PC
researchers, clinicians, and consumer representatives to
identify available options for research prioritisation. Con-
sensus development methods were deemed to be the most
likely to be able to provide stakeholder agreement on PC
research priorities.
The process consisted of ﬁve distinct stages: a literature
review on recent progress in PC research, semi-structured
expert interviews, a Delphi process, consumer focus groups
(FGDs), and a nominal group process (NGP). The literature
review together with expert interviews was used to provide
a ‘‘level playing ﬁeld’’ for all participants, irrespective of
their speciﬁc area of expertise, to facilitate their contribu-
tion to the Delphi process. We decided to use FGDs to
ascertain consumer priorities, in order to maintain an
independent consumer voice throughout the study. Infor-
mation about priorities identiﬁed by the experts through the
Delphi process and by consumers through FGDs were
provided to nominal group participants, to provide them
with a comprehensive picture of potential research priori-
ties to consider and prioritise (see Fig. 1). The study was
approved by the relevant Institutional Ethics Committees.
Literature review
A comprehensive literature review examined the progress
in PC research since 2001, when the NCI multidisciplinary
Progress Review Group published its analysis of the state
of PC research [4].
Expert interviews
Ten international experts took part in semi-structured
telephone interviews discussing the current status of PC
research. Participants were invited to suggest research
directions most likely to provide the next major research
breakthrough in PC, to identify barriers limiting progress in
research, and to identify where Australian research could
make signiﬁcant contributions (see Table 1).
Delphi process
The Delphi method has been developed ‘‘to obtain the most
reliable opinion consensus of a group of experts by sub-
jecting them to a series of questionnaires in-depth inter-
spersed with controlled opinion feedback’’ (p. 458) [6].
Delphi methods commonly involve several rounds of
questioning, with de-identiﬁed individual responses col-
lated, analysed, and summarised before being returned to
respondents in a subsequent round; the process is repeated
until ‘consensus’ is achieved [7]. Modiﬁcations of the
Delphi technique have been used for developing clinical
guidelines and quality indicators [7–12], clinical decision
aids [13], identifying research priorities [14–19], deﬁning
priorities in cancer care [20], and identifying health prac-
titioner’s educational priorities [21].
Delphi participants
The Delphi panel consisted of 27 experts in basic science,
epidemiology, clinical medicine, and policy makers, both
from Australia and overseas. Participants were provided
with the expert group’s recommendations and literature
reviews as background information. Five rounds of ques-
tioning and opinion feedback were conducted, with each
round consisting of collecting de-identiﬁed responses to an
emailed questionnaire. Participant responses were pooled
and analysed by the research group, then circulated again
as ‘feedback’ in a subsequent round [6].
Consumer focus groups
The focus group discussions (FGD) sought participants’
views on key research areas for PC, identifying the unmet
needs of people with PC and inviting comment on initia-
tives that would be most helpful to patients and their carers.
We used FGDs to ascertain consumer views about PC
research, as the ﬂexible nature of questioning allows the
exploration of the wide range of opinions and attitudes held
by participants [22]. We could not identify previous reports
describing ways to engage with PC patients around
research prioritisation, likely related to the difﬁculty of
Background briefs Expert interviews
Consumer focus groups Delphi process
Nominal group
Fig. 1 Diagrammatic representation of the priority-setting process
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lethal cancer.
Conducting FGDs by telephone, rather than in the tra-
ditional face-to-face format was dictated by limitations in
health status and mobility imposed by a PC diagnosis and
allowed patients with advanced cancer and their carers to
become engaged in the priority-setting process with mini-
mal disruption to their lives. One discussion group com-
prised patients with a PC diagnosis, the other involved
current and bereaved carers of patients with PC. Separating
the groups allowed discussions to focus on issues speciﬁc
to each group and how research could address them.
The aim of the research was outlined in a newsletter of
the Pancreatic Cancer Support Project, distributed to
people affected by PC. Interested potential participants
were invited to register their interest in participating
and participants were assured of conﬁdentiality of the
information.
The facilitated discussions were digitally recorded and
subsequently transcribed. Two experienced telephone
support group counsellors facilitated the discussions and an
independent qualitative researcher played an observer role.
Nominal group process
The aim of the nominal group was to elicit participants’
views on PC research priorities most likely to accelerate
progress and to develop consensus around a ﬁnal list of
Australian PC research goals. Participants included clini-
cians (medical and radiation oncologists, surgeons, and
palliative care physicians), pathologists, basic science
researchers, epidemiologists, and nurses.
The process comprised three steps: the identiﬁcation of
new research directions and issues, a discussion about key
research directions identiﬁed through group work and the
reﬁning and tabling of the ﬁnal research goals.
The second step involved each participant selecting and
ranking their top three research priorities, while taking into
account their feasibility within the Australian context. This
involved consideration of existing Australian research
capacity, availability of resources and the potential of the
identiﬁed priorities to deliver a competitive advantage to
Australian researchers. The ranked research priorities were
subsequently discussed within the group and grouped into
categories.
Table 1 Summary results of semi-structured interviews and experts’ recommendations
Discussion topic Issues/salient comments Suggestions
What are key issues in PC research? Late diagnosis leads to poor outcomes
Few effective treatments available
Delays in drug development pipeline
Absence of large, long-term studies
Limited understanding of the genetic
basis of PC
Lack of screening techniques for familial PC
Develop better imaging technologies
Improve screening technologies
Focus on drug discovery
Individualised PC therapy
Pain management in advanced disease
More research on causes of cancer cachexia
Where is the next major breakthrough
in PC research likely to come from?
A blood test for earlier detection
Ability to detect small volume/pre-malignant
disease
Treatments based on tumour biology
The genome sequencing project
Gene discovery in familial PC syndromes
Better understanding of tumour biology
Developing small molecule inhibitors in PC
Identifying genes that can be targeted in
therapy
New animal models for PC
Barriers to progress in PC research—
how can they be addressed?
Limited research funding disadvantages
small research groups and reduces long-
term researcher commitments Relatively
low numbers of PC cases
Lack of good disease models
Limited support from industry for PC clinical
trials
Limited opportunities for collaboration
between disciplines, the public and private
sectors, different countries
Encourage funding of large, long-term
studies
Broaden research collaborations
Develop clinico-pathological databases
Increase opportunities for participation in
clinical trials
Collect more and better epidemiological data
Separate PC from other GI cancer trials
Where are Australian researchers most
likely to make signiﬁcant
contributions to PC research
Australia has well-annotated tissue and blood
samples and a strong epidemiology record
Australia can play a key role in developing
databases and networks to increase research
collaborations
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Literature review
The literature review focussed on ﬁve key areas of research
activity identiﬁed by the NCI Pancreatic Cancer Progress
Review Group: [23] (1) disease aetiology and prevention,
(2) early detection and screening, (3) PC diagnosis,
assessment, and staging, (4) PC treatment and (5) palliative
and supportive care.
Expert interviews
The expert group recommended a focus on the following
research directions: developing better imaging and
screening technologies, identifying genes that can be tar-
geted by therapy, focusing on drug discovery, developing
new animal models for PC, encouraging multidisciplinary
research collaborations, emphasising epidemiological
research and developing well-annotated clinico-pathologi-
cal databases. Australian researchers were perceived to
have a competitive advantage in database development and
developing research networks that could advance PC
research (see Table 1).
The Delphi process
In Round 1, participants were invited to contribute up to
ten issues they believed could change outcomes in PC in
the Australian context (n = 22, 73% response rate), with
responses collated and circulated to the group in Round 2.
As a substantial and very diverse number of research pri-
orities (134) were identiﬁed, a group of PC experts devised
‘research categories’ enabling the grouping of similar or
related items.
In Round 2a, the list derived from Round 1 and grouped
by speciﬁc research category was circulated. Participants
(n = 19, 63% response rate) were invited to conﬁrm
whether the process accurately captured their suggested
priorities and invited to add (or edit) the statements to
better encapsulate their views. These responses were used
to inform Round 2b, where participants (n = 20, 66%
response rate) were asked to nominate their ﬁve top priority
areas from the ﬁnal list. At that stage, research priorities
selected by fewer than 15% of respondents (fewer than two
participants) were excluded, resulting in 14 research pri-
orities progressing to Round 3.
In Round 3, the relevance of these research priorities
was ranked using a Likert scale, from 1 (research unim-
portant) to 5 (research very important); 25 respondents
took part in this round (83% response rate).
Results of this round were circulated to participants in
the fourth and ﬁnal round, ranked in order of their impor-
tance, as identiﬁed in Round 3. Six research priorities
received an average score [4 points, with the remaining
eight priorities averaging between three and four points.
The six highest ranking priorities and their average score
are listed in Table 2.
Consumer focus groups
A range of issues were identiﬁed by both carers and
patients as priorities for PC research. Four main themes
were identiﬁed, related to the following: PC diagnosis,
research into disease causation, better consumer and
practitioner information about PC, and the quality of pan-
creatic cancer care. Different subthemes were identiﬁed
and the information structured using a spreadsheet format.
A summary of issues is presented in Table 3.
There was concordance between the patient and the
carer group as to research priorities in PC, with most rec-
ommendations drawn from individual experiences. Speciﬁc
research recommendations included the following:
researching better modalities to deliver chemotherapy,
reducing the deleterious effects of pancreatectomy on
nutrition, ﬁnding simpler and faster screening tests,
Table 2 Top 6 research priorities identiﬁed by the Delphi process and their average scores
Research priority Rank Average
A better understanding of pancreatic cancer progression, metastases, and resistance to therapy 1 4.28
The establishment of a clinico-pathological database linked with standardised prospectively collected pancreatic
cancer patient data
2 4.21
A better understanding of the early development and progression of pancreatic cancer and its precursor lesions to
facilitate the development of novel early detection, screening, and chemoprevention strategies
3 4.20
The establishment of a pancreatic cancer tissue bank and strategies to encourage participation and support for
this facility
4 4.17
Deﬁne biomarkers of prognosis and therapeutic responsiveness to facilitate the development of stratiﬁed and
individualised therapy
5 4.12
Promoting the development of, and participation in, clinical trials of therapies and management for pancreatic
cancer
6 4.04
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of PC, and exploring the role of genetic testing in disease
prevention.
Nominal group process
New research issues and challenges identiﬁed by partici-
pants included administrative difﬁculties in the research
application process, the impact of an increased use of
complementary and alternative medicines, the need to
distinguish issues germane to research from health delivery
issues, to develop suitable trials for patients with advanced
PC, and expediting the process of clinical trial selection for
this group. In the ﬁnal step, the most frequently listed
research priorities were merged and reﬁned into seven
research goals (see Table 4).
The nominal group recommended the publication and
dissemination of these research goals and suggested that
future grant applications should identify speciﬁc research
challenges and how to address them.
Discussion
This paper summarises a process of research prioritisation
for a cancer which so far has eluded the attention of
funding bodies, despite the signiﬁcant disease burden it
imposes. We used a combination of methods for deﬁning
research priorities, utilising the outputs of two consensus
development methods (Delphi and nominal group pro-
cesses) and focus group discussion to arrive at a list of
‘‘actionable’’ research goals speciﬁc to Australian PC
research. The reason for combining several consensus
building methods was to rule out that ﬁndings being
inﬂuenced by the method chosen, although previous studies
comparing the Delphi method to nominal group found that
Table 3 Priorities identiﬁed by consumer focus groups
Theme 1 Theme 2 Theme 3 Theme 4
Diagnosis of pancreatic
cancer
Research into disease aetiology Better information about pancreatic
cancer
Quality of pancreatic cancer care
Need for earlier diagnosis
….there’s a high priority
for early detection and
an increased focus on
symptoms
What is the role of enzymes and diet
…some more research needs to be
done in regard to what role
enzymes play
More information on signs/symptoms
What I really think we need, like
breast cancer and ovarian people,
is that people have to know what
the symptoms are.
Need to research different treatment
alternatives
I would really like to have the
medical system embrace a little bit
more of alternative medicine
The non-speciﬁc nature of
symptoms delays
diagnosis
I had nothing speciﬁc to
give them, but I knew
something was wrong
Better use pathology specimens
I don’t know what they do with the
organs that have been removed
when they’ve ﬁnished their testing,
but perhaps they could look a bit
further into those
Identify and meet information needs
of patients and doctors
I told him [the doctor] I had had a
Whipple procedure. He had never
heard of a Whipple procedure and
this is a doctor
Deﬁning good quality care
This is what I want—quality care.
With all the drugs and the ups and
the downs, there’s not a lot of
quality there
More information on treatment
options
I was at no time given an option
because I was so shocked and my
type of pancreatic cancer is so
different and very rare
The role of psycho-social support
I believe that anybody who has been
diagnosed with cancer should have
their next appointment, as soon as
possible, with a counsellor
Develop simpler and faster
diagnostic tests––
preferably blood tests
All available treatment options need
to be presented
Some people might even decide to go
overseas for treatment and to try
different things…There are many
other alternatives.
Providing palliative care in rural
areas
I still don’t really understand what
that [palliative care] means and
nobody has actually explained that
to me…
Screen high-risk
individuals
…can we research to have
a diagnosis earlier, such
as some mandatory
procedure for people
over 50?
How doctors break bad news
When the actual ﬁrst diagnosis was
given to us, we had an unfortunate
experience as it was rather brutal.
My wife was told to get her affairs
in order. That’s not treating the
individual as a whole person. We
just felt very badly let down
Changing doctors’ negative attitudes
I’d like to see the medical profession
change their attitudes towards
pancreatic cancer, as in people can
survive and it’s not the end of the
world
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poses [24]. In our study, research priorities generated
through the Delphi process and the NGT were very similar
and echoed consumer priorities identiﬁed through FGDs,
validating our approach. Using a Delphi panel, a modiﬁed
Delphi panel, and a survey-based panel, Brown et al. [25]
identiﬁed medical conditions for which the risk of hospi-
talisation is related to ambulatory care access and found
that consensus techniques had good predictive ability in
this context.
A retrospective review of pancreatic cancer cases repor-
ted to a Cancer Registry in Burgundy (France) made similar
recommendations regarding future PC research: focus on a
better understanding of genetic and environmental causes of
PC, on mechanisms involved in its development and on the
role of diet in PC risk identiﬁed; key challenges related to
detecting early/asymptomatic disease and improvements in
therapy to improve outcomes [26].
Given the variety of opinions that may exist when a
diverse group considers a highly technical and polarising
topic, formal consensus approaches (the Delphi method,
the nominal group process, and the consensus development
conference) are increasingly used to make complex deci-
sion in medicine and health [27]. This is based upon the
ﬁnding that in situations where the evidence limited,
unclear or results diverge widely, consensus methods can
provide ‘‘a bridge between clinical reasoning and clinical
research’’ [28].
Traditionally cancer research priorities have been
determined using a ‘‘group’’ model of decision-making,
where options are advocated for by spokespersons and a
judgement of quality and merit made by the group. While a
wide range of experience and knowledge of group partic-
ipants presents distinct advantages for group models of
work [24], the output of large committees may be sub-
verted by domineering personalities, or because group
members may be unwilling to take a position before all
facts are known, to change it once it is stated publicly, or to
publicly contradict senior participants [29].
Our group chose consensus development methods in
preference to committee or expert reference panels, due to
their perceived limitations and based on the proven track
record of formal consensus methods in achieving research
prioritisation in the health arena [16, 17, 19, 30–34]. It was
encouraging to note also that four of the seven research
priorities identiﬁed by the nominal group arose also from
the consumer FGDs recommendations.
Discussions in the planning phase of the research led to
a decision not to include consumers in the Delphi process,
to safeguard against the potential ‘‘lay disempowerment’’
that may arise when bringing together experts and con-
sumers. Qualitative researchers have questioned whether
the notion of ‘‘empowerment’’ reﬂects participants acqui-
escing researcher’s views, rather than empowerment to
express their own views [35]. While studying Australian
research priorities in mental health, Grifﬁths et al. [36]
found signiﬁcant differences in research priorities between
the committees responsible for evaluating research grants
and consumer and carer groups. We wanted to be able to
identify speciﬁc consumer and researcher perspectives on
research priorities before merging them into a ﬁnal set of
recommendations through the nominal group process.
A telephone-based system can present speciﬁc chal-
lenges for the conduct of FGDs, as important non-verbal
cues may be overlooked in this setting. A key element in
obtaining quality data and providing a good experience to
participants is to ensure that moderators are experienced in
eliciting the views of severely ill patients. In this project,
the FGDs were conducted by a pair of specially trained
telephone counsellors working with people with cancer.
They worked closely with a qualitative researcher with
expertise in conducting FGDs, to ensure that participants
had a positive experience and that all participants had the
opportunity to have their views heard. The FGDs produced
a large amount of key information relatively expeditiously
and in a way that allowed the participation of consumers
who were unwell and would not otherwise have the
opportunity to have their voice heard.
Study limitations
While the Delphi process involved a panel of 27 experts,
their heavy workloads precluded their participation in
every round, so response rates ranged between 63 and 85%
per round. However, the inclusion of multiple rounds—
including a ﬁnal opportunity to dispute or add to the
group’s consensus—enables us to feel conﬁdent that the 14
priorities identiﬁed reﬂect the views of the entire panel.
Table 4 Final list of research priorities identiﬁed by the nominal
group process
1. Deﬁning genetic and environmental factors, which
inﬂuence the overall risk and natural history of PC
2. Deﬁning markers of prognosis and therapeutic
responsiveness, which can facilitate the development
of personalised therapies
3. Developing a better understanding of PC tumour biology and
pancreatic carcinogenesis
4. Developing novel therapies and therapeutic strategies
5. Validating strategies for the optimal, timely, and consistent
management for all disease stages
6. Deﬁning the most common disease and treatment-related
sequelae and identifying strategies for managing them
7. Developing strategies to identify PC at a potentially
curable stage
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used to make statements about what all those affected by
PC think about key research priorities, but the level of
concordance reached independently by patients and carers
would suggest that to some extent at least these results are
generalisable to the larger group. While focus groups are
intended to encourage participants to talk with each other,
rather than answer the moderators’ questions, this pre-
sented speciﬁc challenges for a telephone mode of delivery.
Using experienced support group moderators was essential
in ensuring group interaction and to provide an in-depth
understanding of consumer’s views.
The FGD recommendations, together with the results of
the Delphi process were discussed in a nominal group. This
enabled the list of research priorities to be discussed in a
face-to-face setting, alleviating some of the criticisms
levelled at the Delphi methodology, such as the potential of
manipulating the consensus, unreliability of the process,
and doubts as to what represents acceptable level of con-
sensus [37, 38].
The nominal group deﬁned and ranked seven research
directions for Australian PC research. We critically sum-
marised the ﬁndings of the consensus process and fed them
back to the participants for comment. The priority list was
circulatedtoresearchersintheﬁeld,invitingapplicationsfor
a new funding scheme—the Innovator Grants. The grants
were open to all applicants who addressed the research pri-
oritiesandtheapplicationprocesswassimpliﬁed,inkeeping
with suggestions received from nominal group participants.
Twenty-three applications were received and six were fun-
ded through the new scheme, closing the loop from research
prioritisation to implementation.
Conclusion
This prioritisation exercise provided a much needed ‘‘road
map’’ for research prioritisation in pancreatic cancer, pro-
viding valuable information to researchers applying for PC
research grants. Additionally, the consumer FGDs provided
insights into what patients and their carers see as critical for
PC research: better and earlier diagnostic modalities,
improvements in understanding disease aetiology, high
quality information provision about all aspects of the dis-
ease and its treatment and devising better ways in com-
munication between doctors and patients. It was
encouraging to note that many consumer research priorities
rose to the top of the priority list and will hopefully provide
new research insights in PC.
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